S-nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial and cytoprotective properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 3, 2007, Pages 969-977

  Ishima, Yu ^a,b   Sawa, Tomohiro ^b   Kragh Hansen, Ulrich ^c   Miyamoto, Yoichi ^d   Matsushita, Sadaharu ^a   Akaike, Takaaki ^b   Otagiri, Masaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c AARHUS UNIVERSITY   (Denmark)

^d SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALBUMINOID; ASPARTATE AMINOTRANSFERASE; BIOTIN; FAS LIGAND; LIPRIZZI; LIVER ENZYME; NITRIC OXIDE; R 410 C; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CELL PROTECTION; CELL STRAIN U937; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG HALF LIFE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; LIVER ISCHEMIA; LIVER PERFUSION; MALE; NITROSYLATION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; RAT; SALMONELLA TYPHIMURIUM; STATISTICAL SIGNIFICANCE; ULTRAVIOLET RADIATION;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; CYTOPROTECTION; DISEASE MODELS, ANIMAL; HUMANS; ISCHEMIA; LIVER; MALE; MICE; MICE, INBRED STRAINS; MODELS, MOLECULAR; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; REPERFUSION INJURY; S-NITROSOTHIOLS; SALMONELLA TYPHIMURIUM; SERUM ALBUMIN;

EID: 33847165024     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.114959     Document Type: Article

References (35)

1. Akaike T (2000) Mechanisms of biological S-nitrosation and its measurement. Free Radic Res 33:461-469.
2. Akaike T, Inoue K, Okamoto T, Nishino H, Otagiri M, Fujii S, and Maeda H (1997) Nanomolar quantification and identification of various nitrosothiols by high performance liquid chromatography coupled with flow reactors of metals and Griess reagent. J Biochem (Tokyo) 122:459-466.
3. Bhattacharya AA, Grune T, and Curry S (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 303:721-732.
4. Carter DC and Ho JX (1994) Structure of serum albumin. Adv Protein Chem 45: 153-203.
5. Chen RF (1967) Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 242:173-181.
6. Dworschak M, Franz M, Hallstrom S, Semsroth S, Gasser H, Haisjackl M, Podesser BK, and Malinski T (2004) S-Nitroso human serum albumin improves oxygen metabolism during reperfusion after severe myocardial ischemia. Pharmacology 72:106-112.
7. Ewing JF, Young DV, Janero DR, Garvey DS, and Grinnell TA (1997) Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners. J Pharmacol Exp Ther 283:947-954.
8. Fang FC (2004) Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2:820-832.
9. Foster MW, McMahon TJ, and Stamler JS (2003) S-Nitrosylation in health and disease. Trends Mol Med 9:160-168.
10. Galliano M, Watkins S, Madison J, Putnam FW, Kragh-Hansen U, Cesati R, and Minchiotti L (1998) Structural characterization of three genetic variants of human serum albumin modified in subdomains IIB and IIIA. Eur J Biochem 251:329-334.
11. Hallstrom S, Gasser H, Neumayer C, Fugl A, Nanobashvili J, Jakubowski A, Huk I, Schlag G, and Malinski T (2002) S-Nitroso human serum albumin treatment reduces ischemia/reperfusion injury in skeletal muscle via nitric oxide release. Circulation 105:3032-3038.
12. Hess DT, Matsumoto A, Kim SO, Marshall HE, and Stamler JS (2005) Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6:150-166.
13. Hnatowich DJ, Layne WW, and Childs RL (1982) The preparation and labeling of DTPA-coupled albumin. Int J Appl Radiat Isot 33:327-332.
14. Hogg N (2000) Biological chemistry and clinical potential of S-nitrosothiols. Free Radic Biol Med 28:1478-1486.
15. Ikebe N, Akaike T, Miyamoto Y, Hayashida K, Yoshitake J, Ogawa M, and Maeda H (2000) Protective effect of S-nitrosylated alpha(1)-protease inhibitor on hepatic ischemia-reperfusion injury. J Pharmacol Exp Ther 295:904-911.
16. Iwao Y, Anraku M, Yamasaki K, Kragh-Hansen U, Kawai K, Maruyama T, and Otagiri M (2006) Oxidation of Arg-410 promotes the elimination of human serum albumin. Biochim Biophys Acta 1764:743-749.
17. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, and Snyder SH (2001) Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 3:193-197.
18. Katsumi H, Nishikawa M, Yamashita F, and Hashida M (2005) Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo. J Pharmacol Exp Ther 314:1117-1124.
19. Kim YM, Bombeck CA, and Billiar TR (1999) Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 84:253-256.
20. Konorev EA, Joseph J, Tarpey MM, and Kalyanaraman B (1996) The mechanism of cardioprotection by S-nitrosoglutathione monoethyl ester in rat isolated heart during cardioplegic ischaemic arrest. Br J Pharmacol 119:511-518.
21. Kragh-Hansen U (1993) A micromethod for delipidation of aqueous proteins. Anal Biochem 210:318-327.
22. Kragh-Hansen U, Campagnoli M, Dodig S, Nielsen H, Benko B, Raos M, Cesati R, Sala A, Galliano M, and Minchiotti L (2004) Structural analysis and fatty acid-binding properties of two Croatian variants of human serum albumin. Clin Chim Acta 349:105-112.
23. Liu L and Stamler JS (1999) NO: an inhibitor of cell death. Cell Death Differ 6:937-942.
24. Marks DS, Vita JA, Folts JD, Keaney JF Jr, Welch GN, and Loscalzo J (1995) Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Investig 96:2630-2638.
25. Matsushita S, Isima Y, Chuang VT, Watanabe H, Tanase S, Maruyama T, and Otagiri M (2004) Functional analysis of recombinant human serum albumin domains for pharmaceutical applications. Pharm Res (NY) 21:1924-1932.
26. Mittermayr R, Valentini D, Fitzal F, Hallstrom S, Gasser H, and Redl H (2003) Protective effect of a novel NO-donor on ischemia/reperfusion injury in a rat epigastric flap model. Wound Repair Regen 11:3-10.
27. Miyamoto Y, Akaike T, Alam MS, Inoue K, Hamamoto T, Ikebe N, Yoshitake J, Okamoto T, and Maeda H (2000a) Novel functions of human alpha(1)-protease inhibitor after S-nitrosylation: inhibition of cysteine protease and antibacterial activity. Biochem Biophys Res Commun 267:918-923.
28. Miyamoto Y, Akaike T, and Maeda H (2000b) S-Nitrosylated human alpha(1)-protease inhibitor. Biochim Biophys Acta 1477:90-97.
29. Moncada S and Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012.
30. Richardson G and Benjamin N (2002) Potential therapeutic uses for S-nitrosothiols. Clin Sci (Lond) 102:99-105.
31. Semsroth S, Fellner B, Trescher K, Bernecker OY, Kalinowski L, Gasser H, Hallstrom S, Malinski T, and Podesser BK (2005) S-Nitroso human serum albumin attenuates ischemia/reperfusion injury after cardioplegic arrest in isolated rabbit hearts. J Heart Lung Transplant 24:2226-2234.
32. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, and Loscalzo J (1992) Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 89:7674-7677.
33. Sugio S, Kashima A, Mochizuki S, Noda M, and Kobayashi K (1999) Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 12:439-446.
34. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885.
35. Yamasaki Y, Sumimoto K, Nishikawa M, Yamashita F, Yamaoka K, Hashida M, and Takakura Y (2002) Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors. J Pharmacol Exp Ther 301:467-477.